SecBot SecBot
6-K ·Filed Aug 18, 2026

IMTX

Immatics N.V.
NEUTRAL
Impact 6/10
Horizonweeks Processed3mo ago SEC0001193125-26-354715
Notable filing: 6-K
Actionable Insight • Neutral

The stock is a binary catalyst play on SUPRAME topline (H1 2027). The slower-than-expected event accumulation introduces uncertainty but does not alter the final PFS analysis timeline. The planned enrollment increase for OS power is a positive for commercial profile but adds trial cost. Cash reach into 2028 provides buffer. Near-term price action will be driven by pipeline updates at ESMO in fall 2026. Consider scaling into any weakness ahead of ESMO data.

DirectionNeutral
Confidencehigh
Horizonweeks

Drugs in focus

IMTX drug pipeline →

IMA203

▲ Bullish Named in this 6-K
Impact
Phase
Phase 3
Time to market
If Phase 3 succeeds, BLA submission is planned for 2027 with a potential commercial launch in 2027-2028.
Next catalyst
None dated

What to watchThe binary catalyst is the SUPRAME Phase 3 final PFS readout in H1 2027. Positive data would validate anzu-cel for BLA submission in 2027 and could drive significant upside toward analyst targets (~$17). A negative or underwhelming result would likely hit the stock hard given its current single-asset weighting. Interim operational updates on enrollment could come at the Q3 earnings call on Nov 16, 2026.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$9.09
T+0 close · Aug 18, 2026 · via day close
Latest settled
−29.37%
T+60 · $6.42
Vs SPY
−27.33%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 18 $9.09entry
  2. T+1 · 3mo ago +1.76%α +1.55% · $9.25
  3. T+5 · 3mo ago +1.65%α +1.85% · $9.24
  4. T+20 · 2mo ago −2.97%α −1.98% · $8.82
  5. T+60 · 6d ago −29.37%α −27.33% · $6.42
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Immatics reported Q2 2026 financial results showing a net loss of €62.5M ($71.2M) on collaboration revenue of €9.1M ($10.4M), with R&D expenses rising sharply to €62.4M ($71.1M) as the Phase 3 SUPRAME trial accelerates. Enrollment remains on track to complete by year-end, but PFS events are occurring slower than modeled, prompting a streamlined final analysis (topline H1 2027) and adding ~90 patients for OS power. Cash and financial assets stood at €393.4M ($448.2M), projected into 2028.

Key Facts

  • Q2 2026 revenue: €9.1M ($10.4M) from collaboration agreements (Moderna €6.5M, BMS €2.7M)
  • Q2 2026 net loss: €62.5M ($71.2M), improved from €70.3M ($80.1M) in Q2 2025
  • Cash and financial assets: €393.4M ($448.2M) as of June 30, 2026; cash reach projected into 2028
  • SUPRAME enrollment on track to complete randomizations by year-end; PFS events occurring slower than modeled
  • Company plans streamlined final PFS analysis (topline H1 2027) with 90% power, adding ~90 patients for OS
  • BLA submission planned in 2027 following PFS topline
  • Phase 1b anzu-cel data at ASCO 2026: 56% cORR, 14.6 mo mDOR, 6.1 mo mPFS, 16.2 mo mOS in melanoma
  • IMA203CD8 Phase 1 data in gynecologic cancers: 63% ORR, 50% cORR at clinically relevant doses
  • IMA402 bispecific Phase 1b data at RP2D range expected at ESMO 2026
  • First patient dosed in Moderna collaboration trial (mRNA-4200) in July 2026, triggering milestone payment
  • R&D expenses Q2 2026: €62.4M (up 38% YoY from €45.1M), driven by SUPRAME trial costs
  • Net cash used in operations H1 2026: €102.5M vs €73.3M in H1 2025

Financial Impact

Net loss of €62.5M in Q2 2026, operating cash burn of €102.5M in H1 2026, cash runway into 2028

revenuenet lossoperating expensescash positiondilution

Risk Factors

  • SUPRAME PFS topline data (H1 2027) could miss expectations if slower event rate signals lower separation from standard of care
  • R&D burn is accelerating (€121.6M in H1 2026 vs €87.0M in H1 2025) with no near-term product revenue
  • Competitive landscape for cell therapies in melanoma (lifileucel, RP1, etc.) could narrow market opportunity
  • Reliance on collaboration revenue (Moderna, BMS) for near-term cash flow

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
94% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001193125-26-354715
Document: imtx-ex99_2.htm0001193125-26-354715
Document: imtx-20260630.htm0001193125-26-354715
Document: imtx-ex99_3.htm0001193125-26-354715
Document: 0001193125-26-354715-index-headers.html0001193125-26-354715
Document: 0001193125-26-354715-index.html0001193125-26-354715
Document: 0001193125-26-354715.txt0001193125-26-354715

Track record

23 reports on IMTX

Performance horizon

8 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +22.12% at T+20 after the May 12, 2026 report. 9 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $6.24 Now $6.17 −1.12% settles Nov 23
  2. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $6.55 Now $6.17 −5.73% settles Nov 23
  3. Nov 10, 20266d ago 6-K Neutral 5/10 No price data
  4. Nov 10, 20266d ago Press Release Neutral 4/10 Entry $6.42 Now $6.17 −3.89% settles Nov 17
  5. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
  6. Oct 24, 202624d ago Press Release Bullish 6/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
  7. Oct 23, 202624d ago 6-K Bullish 7/10 Entry $7.31 to $7.20 Now $6.17 −15.60% ▼ −1.50% −0.95% vs SPY
  8. Aug 27, 202611w ago Insider Buy Bullish 6/10 Entry $9.45 to $9.56 Now $6.17 −34.71% ▲ +1.16% +1.05% vs SPY
  9. Aug 26, 202611w ago 6-K Bearish 6/10 Entry $9.36 to $9.46 Now $6.17 +34.08% ▼ −1.07% −0.80% vs SPY
  10. Aug 18, 202612w ago 6-K Neutral 6/10 Viewing Entry $9.09 to $9.24 Now $6.17 −32.12% ▲ +1.65% +1.85% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 18, 2026